article thumbnail

UK agency pilots biobank to study links between genetics and drug side effects

Pharmaceutical Technology

The Medicines and Healthcare products Regulatory Agency (MHRA) aims to launch a pilot genetic biobank that will gather patient data to associate drug-related adverse events to their genetic makeup. The Yellow Card biobank will launch as a joint venture with the UK-government funded entity Genomics England on June 1.

article thumbnail

A new dawn of the genomic age: five areas set to be transformed in 2023

pharmaphorum

2022 was a banner year for genomics. In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA.

Genome 129
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Why genomic healthcare data matters in the development of new therapies 

Drug Discovery World

Genomic healthcare data is critical to identify disease risk, ancestry, traits and response to medicines and aids in the development of new targeted therapies – precision medicines. In April 2003, after its launch in October 1990, the project was completed, generating the first sequence of the human genome. The origins .

Genome 98
article thumbnail

Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data

The Pharma Data

to build a scalable data, analytics, and infrastructure platform This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine. Boehringer Ingelheim partners with Lifebit Biotech, Ltd.

article thumbnail

Can genetic data be a magic bullet for drug R&D?

pharmaphorum

The cost of testing per human genome in 2006 was approximately $14 million , and in less than two decades, an average consumer-purchased genetic test costs $100. The same is becoming true for the healthcare industry, and one of the first major breakthroughs in the area was the 100,000 Genomes Project.

article thumbnail

Estonia National Biobank to sequence 10,000 whole genomes 

Drug Discovery World

The university will also support the European Union’s 1+ Million Genomes initiative, which seeks to boost innovation in healthcare across Europe. Driving new understanding 10,000 whole human genomes will be sequenced and analysed by the Institute of Genomics at the University of Tartu.

article thumbnail

Q&A: Gene therapy opportunities from long-read sequencing 

Drug Discovery World

To develop safe and effective gene therapies, researchers need confidence that genomic data is both complete and accurate. This considerable magnitude of difference in read length affords researchers a more complete and accurate view of genomic variation. For years now the UK has been somewhat of a leader in genomic research.